Exp Neurobiol 2015; 24(4): 341-350
Published online December 30, 2015
© The Korean Society for Brain and Neural Sciences
Ji-Seon Seo1, Juli Choi1, Yea-Hyun Leem2,3 and Pyung-Lim Han1,2,3*
1Department of Brain & Cognitive Sciences, 2Department of Chemistry & Nano Science, and 3Brain Disease Research Institute, Ewha Womans University, Seoul 03760, Korea
Correspondence to: *To whom correspondence should be addressed.
TEL: 82-2-3277-4130, FAX: 82-2-3277-3419
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons in the brain and spinal cord, resulting in paralysis of voluntary skeletal muscles and eventually death, usually within 2~3 years of symptom onset. The pathophysiology mechanism underlying ALS is not yet clearly understood. Moreover the available medication for treating ALS, riluzole, only modestly improves neurological symptoms and increases survival by a few months. Therefore, improved therapeutic strategies are urgently needed. In the present study, we investigated whether rosmarinic acid has a therapeutic potential to alleviate neurological deterioration in the G93A-SOD1 transgenic mouse model of ALS. Treatment of G93A-SOD1 transgenic mice with rosmarinic acid from 7 weeks of age at the dose of 400 mg/kg/day significantly extended survival, and relieved motor function deficits. Specifically, disease onset and symptom progression were delayed by more than one month. These symptomatic improvements were correlated with decreased oxidative stress and reduced neuronal loss in the ventral horns of G93A-SOD1 mice. These results support that rosmarinic acid is a potentially useful supplement for relieving ALS symptoms.
Keywords: Rosmarinic acid, ALS, neuroprotection, antioxidant